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| INTRODUCTION
Dual antiplatelet therapy with aspirin and an ADP P2Y 12 inhibitor is the current standard treatment for patients with an acute coronary syndrome (ACS) undergoing percutaneous coronary intervention (PCI) with stent implantation. [1] [2] [3] [4] [5] The newer P2Y 12 receptor antagonists prasugrel and ticagrelor offer more potent platelet inhibition than clopidogrel and were shown to significantly reduce adverse ischemic outcomes following an ACS compared with clopidogrel. 6, 7 However, despite the increasing use of prasugrel and ticagrelor, further atherothrombotic events still impair the prognosis of many ACS patients. verse ischemic events occurred in 6.6% of prasugrel-and 5.7% of ticagrelor-treated patients. 8 The latter has been explained by the fact that a significant number of patients were switched to clopidogrel after hospital discharge, but might in part also be attributable to intact platelet aggregation via the human thrombin receptors protease-activated receptor (PAR)-1 and PAR-4.
9-11
Thrombin is a strong endogenous platelet agonist, leading to platelet activation at subnanomolar concentrations. 12 It acts as a multifunctional serine protease, which activates human platelets predominantly via PAR-1 and, to a lesser extent, PAR-4. [13] [14] [15] PAR-1 is activated by low thrombin concentrations and amplified by PAR-4 signaling as the thrombin concentration rises. 11, 16 Thus, both PAR-1 and PAR-4 need to be blocked for full inhibition of thrombin-induced platelet activation.
The activation of platelets by thrombin leads in turn to ADP release, promoting further recruitment, adhesion, and aggregation of activated platelets via stimulation of P2Y 1 and P2Y 12 receptors. Accordingly, P2Y 12 inhibition also affects PAR-mediated platelet aggregation.
17
In the past, we have demonstrated that platelets can still be activated via PAR-1 and PAR-4 despite P2Y 12 inhibition by clopidogrel. 18 In the current study, we sought to investigate if platelet aggregation via PAR-1 and PAR-4 persists in ACS patients receiving the newer and more potent P2Y 12 antagonists following PCI with stent implantation.
| METHODS

| Study population
The study population consisted of 194 ACS patients on daily aspi- 
| Blood sampling
Blood was drawn by aseptic venipuncture from an antecubital vein using a butterfly needle (21-gauge, 0.8 × 19 mm; Greiner Bio-One, Kremsmünster, Austria) 72 hours after PCI. To avoid procedural deviations, blood sampling was performed by the same physician applying a light tourniquet, which was immediately released, and the samples were mixed by gently inverting the tubes. The initial 3 mL of blood were discarded to reduce periprocedural platelet activation. Afterwards, blood was drawn into hirudin-coated tubes (Roche Diagnostics, Mannheim, Germany) for multiple electrode aggregometry (MEA).
| Multiple electrode aggregometry
Whole blood impedance aggregometry was performed using the Multiplate analyzer (Roche Diagnostics) as previously described. 17, 18 In brief, hirudin-anticoagulated whole blood was diluted 1:2 with 0.9% NaCl solution and stirred in the test cuvettes for 3 minutes at The determined dosages corresponded to the concentrations
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recommended by the manufacturer. The increase of impedance that was evoked by the adhesion of activated platelets to the electrodes was detected by each sensor unit separately, transformed to AU and plotted against time.
| Statistical analysis
Statistical analysis was performed using the Statistical Package for Social Sciences (SPSS version 24.0; SPSS, Chicago, IL). Median and interquartile range of continuous variables are shown. Categorical variables are given as number (%). We performed the nonparametric Mann-Whitney U-tests to detect differences in continuous variables. The chi-square test was used to assess differences in categorical variables. Spearman correlation was used to test for correlations between platelet aggregation in response to the different agonists.
Two-sided P values <0.05 were considered statistically significant.
| RESULTS
Clinical, laboratory, and procedural characteristics of the study population are given in Table 1 . As expected, ticagrelor-treated patients (n = 80) were older than prasugrel-treated patients (n = 114; P = 0.02) and had significantly higher serum creatinine levels (P = 0.001). Calcium channel blockers, n (%) 10 (9) 9 (11) 0.57
Angiotensin receptor blockers, n (%) 16 (14) 18 ( In accordance with data from others, the rate of HRPR ADP was low in prasugrel-treated patients, and HRPR ADP was not seen in patients on ticagrelor, [24] [25] [26] 12.7%; P = 0.02). . 43 On the other hand, major bleeding events including intracranial hemorrhage were significantly increased in patients receiving vorapaxar in both trials. 42, 43 Consequently, vorapaxar should not be prescribed in all ACS patients but may become a treatment option for patients with a high risk of ischemic cardiovascular events and a low bleeding risk.
In a previous study, we showed that high on-treatment PAR-1-mediated platelet activation is a strong predictor of ischemic outcomes in PAD patients following peripheral angioplasty and stenting. 44 Furthermore, in a post hoc analysis of the TRA°2P-TIMI-50 trial, vorapaxar demonstrated its positive effects on adverse ischemic events vs. placebo in PAD patients. 45 Based on our observation of preserved platelet aggregation via PAR-1 in many prasugrel-and ticagrelor-treated patients, one may speculate that the measurement of PAR-1-mediated platelet aggregation may allow the identification of ACS patients who might benefit from additional vorapaxar therapy despite being already treated with potent P2Y 12 inhibitors. Moreover, PAR-4 might be a potential new target for antiplatelet therapy in patients with high PAR-mediated platelet aggregation. 4, 11 Indeed, it has recently been shown that PAR-4 antagonism reduces thrombin response by >50%. 4, [46] [47] [48] It must be taken into account that a combination of vorapaxar with stronger P2Y 12 inhibitors might impact on bleeding as also a combi- Acute Coronary Syndrome) trial. 50 As in the phase III trials investigating vorapaxar, the rates of major and intracranial bleeding were higher in the rivaroxaban groups than in patients receiving placebo. Limitations of our study are the lack of clinical outcome data, its observational design, and the fact that we measured platelet aggregation at only 1 time point using a single test system.
Moreover, we did not perform in vivo analyses. However, MEA is a highly standardized platelet function test ensuring a good comparability of the obtained results with other laboratories, and platelet aggregation by MEA has repeatedly been linked to cardiovascular outcomes following PCI. 20, 21 Another limitation of our study is that the cutoff values for PAR-1-and PAR-4-mediated platelet aggregation were derived from measurements in healthy volunteers, who were not on any medication and not age-matched to the patient population. However, by defining the upper 95% of PAR-mediated platelet aggregation in the control group as normal uninhibited platelet aggregation, we eliminated possible low outliers.
Finally, it must be mentioned that studies trying to individualize antiplatelet therapy based on platelet function testing have failed so far.
In conclusion, normal platelet aggregation via PAR-1 and PAR-4 is preserved in many ACS patients despite adequate P2Y 12 inhibition by prasugrel and ticagrelor. The present findings may in part explain the occurrence of adverse ischemic events despite potent P2Y 12 inhibition. Future trials are warranted to investigate the association of PAR-mediated platelet aggregation with clinical outcomes in ACS and to study potential therapeutic approaches.
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